Part 1: 2024 Hatch-Waxman Year in Review

In today's episode, first in a two part series, we’re going to unpack the year in review for the Hatch-Waxman Act—a critical framework in the pharmaceutical industry that continues to shape the dynamics between brand-name drugmakers and generics.  2024 has been a fascinating year, with significant trends and legal shifts that have implications for innovation, accessibility, and regulatory strategy. Whether you’re a legal professional, a business leader in pharma, or simply interested in the interplay between patents and healthcare, this episode will give you key insights into what shaped the legal landscape this year.  Read the full article2024 Hatch-Waxman Year in ReviewAbout the authorsBen BourkeAlexander P. Wharton